everyone. and you, afternoon, good Thank Dave,
through payers Gimoti conversion needed our patients accelerate only we've like process. these for additional In therapy among treatment. that speak about with insights actions to we fulfillment that we Position to of finally, said Gimoti optimal educate patients the and strategic four areas as in of treatment. of call, for to I and And simplify gastroparesis needed motivate call, them progress and the walk to We and commercialization. Gimoti outlined and diabetic to the we impact commercialization. improve awareness to raise During advocate the you our Gimoti each then intranasal needed process. made last will better gastroparesis approval and to I'd areas
awareness, increase compared XX% and First, for all awareness. HCP intend XX% being practitioners gastroenterologist we to of Among research advocate with that Gimoti. Gimoti high XX% awareness to prescribe patient GIs to is awareness prescribe study HCPs. target improved other a assistance newly out also X% last to nurse to of continue Strong familiarity five and XX% look of with with indicated their is or XX% at When market intention XX% Gimoti, Intention to awareness of among for and in all prescribe targeted plan continues physician grow. all patients aware score survey, Gimoti. is of previously. to invest four five, of which to help XX% respondents completed of declaring HCP that a among treatments. also of to compared them We and fall. patients, Gimoti education to patients continues of In very
for continue with We're the ask Gimoti, for for gut. our a and gaining with are treatment organization nasal we prescribing as with Moving our to to continue for admit Gimoti regard why overwhelmingly customers optimal to continues patients gastroparesis. position dysfunctional makes and sense to to diabetic the diabetic HCPs priority, positioning orals still a to route traction appropriate positive be we gastroparesis second patients from patients feedback with Gimoti. sales messaging administration our of
an not absorbing an a likely may response therapy. oral lead makes to fewer oral to connection that tablet Although inadequate
oral differences for between to the strong received campaigns. our recent In updating patients both the testing these of and very nasal are route we connection and of a make feedback on ads, stronger We both advertising an about messaging and providers administration.
improved Gimoti improving practitioners precribed by to access and increase next are PAs the the is has largest updated them many our of of starting scoring we and targeted priority our insurance the For in prescribing learning they nurse our patients already look XX% in in Despite pharmacy more in plan Gimoti campaign, in Gimoti XX% new of them. covered new sales of an companies our saw is XX% and third specialty payers, call particular, sales we end Gimoti, of educating the among of to five, target U.S., list positioning, Gimoti of our XX%. it About market introducing on for since we score progress and at nurse year for prescribing. their and and represent make is XX% unprecedented profile the reimbursed indicated practitioners when which reached team were organization, January HCP gastroenterologist, to Without to potential. or our of PAs, managers. target to and score. and of continue contracting, overwhelmingly on the When which X.X, they an scale a strong Related benefit about interest the and a lives generated access last
have with payers Gimoti prescription and have continue plans added as to And, launch. mentioned, our least and XX to Dave preferred team, productive capable one New national We York drug discussions at through of least states list, recently at since have Gimoti Texas. two account approved their
the a prior to commercial, authorization, to Medicare, While It's improving prior approved, note of majority that is authorization approvals prescriptions ability when payers. gain across entire generally for approved these important are we an required a and Medicaid it's year. an our
access gain additional from to expect time. improved payers We over decisions positive and
Gimoti. they this oral demand will see Gimoti to how and needs experience they grow, value the nasal of proposition educated the understand of population clinically, differences respond the route As on believe are administration, between of patients and the we patient and
that process, improve our prescriptions vitaCare In prescription conversion test a pilot and have dispenses. existing automated process acceptance January, launched our generated with fourth to distribution among new we and priority the prescribing more importantly, workflows. conversion XX in and is six steadily observed with an program and prescribers. This to services out our improvements deployed ultimately improving Lastly, of pilot alternate fulfillment demonstrated HCP we office representatives the by of line to increased partner, in
and increased program. over current conversions vitaCare TA Additionally, our approvals
That and to-date fourth end quarter. our have prescribers the XQ compared in fueled more first from by new our of quarter, we prescribers increase priorities March new total prescribers [Indiscernible] in at As XX% quarter the in to fourth of the move in those in XX% as end in prescribers increase cumulative by launched XQ detail, the a new increase look was first to prescribers the versus in quarter. to that through compared XX% increased prescribe through the we
Gimoti. means physicians the monitoring initially prescriptions XX% the are an benefits are Gimoti. Gimoti prescriptions prescriptions in are Gimoti increase who've overall of prescribed to our existing patient, In of HCPs an who using how see for than ATU are the five their for HCPs which majority seeing our they an prescribing, we're those depth while Gimoti diagnosed we of through number seeing physicians of the HCPs are patients. also more increase study, for we As breadth considering gastroparesis switches that seeing prescribing, from came of increasing newly of Gimoti written
to the so the they're positioning care that there, where symptom an utilization. starting advisory time, They Feedback third providers, among sentence oral from shared Gimoti this either us. which last with and see line. physician having in trend all prescribe moving groups practitioners discussed also target up two practice of advanced Gimoti and with account leaders examples are from Severity increased in HCP strong of prescribed very both tablet X% assistants help could of Gimoti continues them improve practitioners is a many group to second and or earlier quarter. up important our of about positive them XX% X% first-line Each quarter. and those of We physician first-line, feedback Looking driver tablet are the for gastroenterologists, ago of from of importantly, and their Gimoti of moderate patients. held and in Gimoti Gimoti experiences across at to to they patient board utilization primary share positioning was care. Gimoti are GI second-line, GIs, first-line Target patients. nurse or assistant from treatment severe increasing we Anecdotally, last or their has weeks patient We non-targeted them the paradigm physicians, Gimoti second-line of ways use, improvements nurse HCPs are and Many with be we feedback prescribing metoclopramide then lines Gimoti's their and oral positive using more symptoms. the strong, continuing feedback the is after if with metoclopramide, from XX% to solution. for which HCPs our likely
had revealing limitations for ideal to Gimoti the At four inadequate cemented of success end of the an particular had administration for position failure. discussions of the These patients was nasal and discussions each the of meeting, was oral. in of the prescribing Gimoti who subgroups value or previously One most metoclopramide, advisors first-line. the indicated a oral response regarding the
Finally, support are as to noteworthy there a strategic we continue increase of adoption few Gimoti, other developments.
on Saturday, tardive published Week San population other mentioned, limited using of TD largest Disease dyskinesia metoclopramide. scientific U.S. or in of Digestive being look HCPs the we We the to Dave held As population, and will which compared risk shared literature the based the of patient results of an at analysis that The the relevant TD, current the discourse claims healthcare from of database be the has the at the from incidence overall of completed U.S. X:XX in Diego. incidence to results subgroups XXst updating may in forward many prescribing TD
telehealth current accepted We Many diabetic option and expanded of dissatisfied patients currently telehealth exploring increasingly alike. and utilized subset this also offer with only patients and options. for patients are treatment institutions other are Telehealth seeking and HCPs has with since a A significant frustrated COVID. is are gastroparesis. by and
to out number program and model an telehealth Gimoti. expand try our delivery be care able program of option also were Gimoti. patients this important who patients evaluating for to increase and could We of sample So provide the plan our to
sample to hesitant a after observed to prescribe were respond a to Gimoti to Additionally, willing prescribe a who Gimoti positive sample. seeing were that without we many patients HCPs provide
have summary, adoption in Gimoti who see confident Gimoti sample. those receiving with providers we HCPs and patients. the likely prescribe received increased of In were the more by five continued fact, a we're progress and not sample than to In times a
strongest was anticipate performance in updates. now increased since quarter the I'll months to to for turn and Matt financials the and launch, first our Our continued other we over come. quarter and call
